We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appeals court upheld that a Novartis patent for its multibillion-dollar MS drug Gilenya is invalid, opening the door for generics as early as 2019. Read More
The Justice Department searched Perrigo’s corporate offices as part of a broad investigation into pharmaceutical industry drug pricing practices involving several companies. Read More
Pfizer called for the invalidation of three Rituxan patents covering treatments for non-Hodgkin lymphomas last week, filing separate complaints with the PTO’s patent review board. Read More
More than a dozen states are considering drug price transparency bills — most recently in California, where a state senate committee voted to advance legislation requiring drugmakers to disclose operating costs. Read More